MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.?s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company?s Scientific Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
365 GBX | -1.35% | 0.00% | +3.55% |
05-08 | MaxCyte Shares Rise Sharply After Q1 Results Beat | MT |
05-08 | MaxCyte shares rise amid double-digit revenue increase | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.55% | 490M | |
+12.85% | 229B | |
+13.88% | 195B | |
+18.39% | 142B | |
+28.78% | 109B | |
+2.09% | 64.85B | |
+18.24% | 54.33B | |
+7.04% | 52.09B | |
+10.83% | 45.15B | |
+5.94% | 37.39B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer